Svalinn Therapeutics, Inc

Svalinn Therapeutics, Inc., based in Seattle, WA, is focused on developing a safer radical cure for malaria, a disease that threatens 40% of the world's population. With an alarming statistic of 274,000 children under the age of five dying from malaria in 2019 alone, the company aims to address genetic barriers that hinder effective treatment for a significant portion of the affected population.

The company is working on a modified therapeutic regime for Plasmodium vivax, which will enable all individuals, regardless of their enzyme status, to be cured of this disease. Svalinn Therapeutics is committed to ensuring that no one suffers lifelong recurrences of malaria or passes it on to others.

Generated from the website